A Mab A Case Study In Bioprocess Development [2025-2026]

For bioprocess engineers and scientists, every new Mab is a new case study. And every case study, like Mab-X, is a step toward safer, more affordable biologics for patients worldwide. This article is a synthetic case study representative of standard industrial practices for monoclonal antibody development. Actual processes for commercial antibodies (e.g., Humira, Keytruda, Rituxan) vary in specifics but follow the same engineering principles outlined above.

The remaining HCPs and DNA carry a negative charge at pH 8.0. Mab-X, with a pI of 8.5, flows through a Q Sepharose FF column. This step reduces HCP to <30 ppm and DNA to <1 pg/mg. Part 4: Formulation and Drug Substance – The Final Barriers The purified Mab-X is now in a low-pH, high-salt buffer unsuitable for injection. The case study addresses two final challenges: 4.1 Concentration and Diafiltration Using tangential flow filtration (TFF) with 30 kDa cassettes, the team concentrates Mab-X from 2 mg/mL to 120 mg/mL. Viscosity becomes the enemy. At 100 mg/mL, viscosity reaches 25 cP, causing high pump shear and membrane fouling. A Mab A Case Study In Bioprocess Development

Mab-X binds to a strong cation exchanger (Poros 50 HS) at pH 5.5. The team runs a shallow salt gradient (0 to 150 mM NaCl over 30 column volumes). This resolves the main peak from the deamidated variant, which elutes slightly earlier. Collection windows are narrowed to 70-85% of peak height, discarding tails. For bioprocess engineers and scientists, every new Mab